ABSTRACT
I
ntracranial atherosclerosis is an important cause of cerebral ischemia with a relatively high prevalence in Chinese patients. 1 The Chinese Intracranial Atherosclerosis study reported a prevalence of intracranial stenosis of 46.6% among 2864 consecutive Chinese patients with cerebral ischemia. 2 Patients with ischemic symptoms related to high-grade intracranial stenosis (70%-99%) have an almost 20% risk of recurrent stroke within 1 year despite antithrombotic treatment. 3 Therefore, intracranial angioplasty and stent placement have been recommended to reduce the rate of recurrent ischemic events. [4] [5] [6] [7] However, the Stenting versus Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial 8 was prematurely terminated due to excessively high 1-month stroke and/or death rates in patients randomized to intracranial stent placement. At the time of the Data Safety Monitoring review, 14.7% of patients treated with angioplasty combined with stent placement experienced a stroke or died within 1 month after enrollment compared with 5.8% of patients treated with medical therapy alone, a highly significant difference. 1, 9 The 1-month stroke and/or death rate was much higher than the 6.6%, 4.5%, and 6.5% rates in the prospective Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA) study, 10 Wingspan study, 11 and Apollo Stent for Symptomatic Atherosclerotic Intracranial Stenosis (ASSIST) study, 12 respectively. Possible reasons for the disproportionately high rates of 1-month stroke and/or death included a very short time interval between the index ischemic event and the procedure, lack of stratification by ischemic event type, and less rigorous operator-experience requirements. 13 The Food and Drug Administration in March 2012 announced that the Wingspan stent system (Stryker Neurovascular, Kalamazoo, Michigan) continues to remain an option for patients with recurrent stroke despite medical management who have not had any new stroke symptoms within 7 days before treatment with the Wingspan. The decision was based on review of the SAMMPRIS trial and the clinical study data supporting humanitarian device exemption approval data, supplemented by the opinions of an advisory panel of experts. The manufacturer, Stryker Neurovascular, was also required to enhance its physician training program for the Wingspan stent. Another expert panel concluded that the SAMMPRIS trial data support modification but not discontinuation of the use of intracranial angioplasty and/or stent placement for intracranial stenosis. 13 The panel further recommended proceeding with another clinical trial with appropriate modifications in design based on lessons learned from the SAMMPRIS trial to avoid unnecessary elimination of a potentially beneficial treatment in appropriately selected patients.
On the basis of the above-mentioned considerations, a multicenter prospective single-arm trial with independent outcome ascertainment was undertaken to determine whether such modifications will result in lower rates of periprocedural 1-month stroke and/or death in patients treated with intracranial stent placement.
MATERIALS AND METHODS

Patient and Site Selection
The study was an investigator-initiated, government-funded, prospective, multicenter registration trial that was conducted at 10 clinical sites in China. Patients who had experienced a recent TIA or nondisabling ischemic stroke (modified Rankin Scale score, Յ2) caused by high-grade stenosis (70%-99% in severity) of a major intracranial artery (middle cerebral artery [M1], intracranial internal carotid artery, intradural vertebral artery, and basilar artery) were eligible. Conventional angiography was used to quantitate the severity of stenosis by using the Warfarin-Aspirin Symptomatic Intracranial Disease Study criterion. 3 Patients who had ischemic symptoms within the most recent 3 weeks were excluded. Patients with perforator strokes only were not considered candidates for stent placement. Here, perforator strokes due to perforator occlusion are defined as basal ganglia or brain stem/thalamus infarction related to middle cerebral artery or basilar artery stenosis. The inclusion and exclusion criteria for the trial are provided in Table 1 and On-line Table 1 . This study is registered in the ClinicalTrials.gov with ID NCT01763320 (China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis). The 10 participating sites were selected on the basis of the volume of procedures performed. At each site, the annual volume of intracranial angioplasty and stent placement procedures performed was Ͼ30 procedures for the past 3 years. At each site, the study team consisted of a neurologist, a neurosurgeon, a neuroradiologist, and a research coordinator. The study protocol was reviewed and approved by a central Data Safety Monitoring Board and subsequently by the local institutional review board. Each patient signed a written informed consent before the procedure. Relevant data were recorded on a standard case reporting form.
Treatment Protocol
The patients were placed on aspirin, 100 mg daily, and clopidogrel, 75 mg daily, for 3-5 consecutive days before the proce- radiation-induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of the central nervous system; postpartum angiopathy; suspected vasospastic process; and suspected recanalized embolus 2) Symptomatic intracranial stenosis: presenting with TIA or stroke within the past 12 months attributed to 70%-99% stenosis of a major intracranial artery (internal carotid artery, MCA ͓M1͔, vertebral artery, or basilar artery) 3) Degree of stenosis: 70%-99% severity confirmed by catheter angiography for enrollment in the trial 4) Remote infarctions on MRI were acceptable, which could be accounted for by the occlusion of the terminal cortical branches or hemodynamic compromise (perforator strokes excluded); perforator strokes due to perforator occlusion are defined as basal ganglia or brain stem/thalamus infarction related with middle cerebral artery or basilar artery stenosis 5) Expected ability to deliver the stent to the lesion 6) All patients should be treated beyond a duration of 3 weeks from the latest ischemic symptom onset 7) No recent infarctions identified on MRI (indicated as high signals on DWI series) at enrollment 8) No massive cerebral infarction (more than one-half of the MCA territory), intracranial hemorrhage, epidural or subdural hemorrhage, and intracranial brain tumor on CT or MRI 9) mRS score of Յ2 10) Target vessel reference diameter must be measured at 2.00-4.50 mm; target area of stenosis is Յ14 mm in length 11) No childbearing potential or has a test negative for pregnancy within the week prior to study procedure; female patients had normal menses in the past 18 months 12) Patient is willing and able to return for all follow-up visits required by the protocol 13) Patients understand the purpose and requirements of the study and have signed an informed consent form dure. The procedure was performed with the patient under general anesthesia in all except 1 case. The case was typically performed via a transfemorally placed 6F-long sheath or guiding catheter. The intracranial stenotic lesion was traversed by using a standard 0.014-inch microcatheter-microguidewire system by using high-magnification fluoroscopic road-mapping techniques. The microcatheter was exchanged over a 300-cm-long 0.014-inch microguidewire for a Gateway angioplasty balloon (Stryker Neurovascular). After angioplasty, the Gateway angioplasty balloon catheter was exchanged over the existing 0.014-inch microguidewire for a self-expanding nitinol Wingspan stent delivery system. In general, the Wingspan stent diameter was 0.5-1.0 mm greater than the target artery and was deployed to extend at least 3 mm on either side of the lesion. 11 The Wingspan was deployed across the lesion by using the standard technique of outer containing catheter withdrawal. If the residual stenosis after Wingspan stent deployment was Ͼ50% in severity, the study protocol allowed postdilation with a new angioplasty balloon catheter. Technical success was determined by successful placement of the stent across the lesion and residual stenosis of Ͻ50% on postprocedural angiography. Throughout the procedure, intravenous heparin boluses were given to maintain the activated clotting time between 250 and 300 seconds. The protocol required frequent measurements of blood pressure during the procedure and at least 1 measurement every half an hour during the next 24 hours while the patient was monitored in an intensive care unit. The systolic blood pressure was maintained between 100 and 120 mm Hg for 24 hours after the procedure. The patient was continued on aspirin, 100 mg daily, and clopidogrel, 75 mg daily, for the next 90 days and subsequently on aspirin alone. Concurrent risk-factor modification was undertaken, consisting of normalizing low-density lipoprotein (statins, target low-density lipoprotein of Ͻ2.58 mmol/L [100 mg/dL]), hypertension (systolic pressure of Ͻ140 mm Hg and diastolic pressure of Ͻ90 mm Hg), and glycemic status (in patients with diabetes, the hemoglobin A1c level was checked with a target level of Ͻ6.5%), and lifestyle modification.
14
End Point Definition and Ascertainment
Primary end points included any stroke and/or death within 1 month. A stroke was defined as a sudden-onset neurologic deficit that persisted for at least 24 hours and could be ischemic or hemorrhagic in nature. Ischemic stroke was further defined as a new focal neurologic deficit that was not associated with an intracranial hemorrhage on brain CT or MR imaging. Hemorrhagic stroke was defined as parenchymal, subarachnoid, or intraventricular hemorrhage detected by CT or MR imaging that resulted in a stroke (as defined above) or seizure. The hemorrhage was classified as asymptomatic if symptoms or signs were temporary (lasted Ͻ24 hours) without any seizures. 15 Asymptomatic strokes were considered adverse events but were not included as primary end points. At each site, the site-designated neurologist who was not part of the treating team ascertained the clinical outcomes within the 1-month follow-up. The neurologist along with the study coordinator performed each follow-up visit and collected the data regarding study end points.
Statistical Analysis
The statistical methods used were predominantly descriptive. Continuous data were presented as means (with SDs), and categoric data were presented as percentages. For selected percentages, 95% confidence intervals were calculated by using the binomial (Clopper-Pearson) "exact" method. 16 
RESULTS
From July 2013 to March 2014, 10 participating sites evaluated 235 consecutive patients with symptomatic high-grade intracranial stenosis or occlusion (70%-100% in severity by angiography). Among them, 135 patients were finally excluded from the study because of the following aspects: 1) Patients did not meet the inclusion criteria; 2) refused to accept endovascular stent placement; and 3) had chronic occlusion of target major intracranial artery. A total of 100 intracranial lesions were treated in 100 enrolled patients (median age, 56 years; 73% were men) ( Table 2 ). All procedures were a combination of angioplasty followed by stent placement performed with the patient under general anesthesia (except 1 case) via the femoral approach. None of the patients required additional postdilation or Ͼ1 stent placement. Angioplasty and stent placement were performed in the following locations: 27 (27%) in the basilar artery, 17 (17%) in the intracranial internal carotid artery, 38 (38%) in the middle cerebral artery, and 18 (18%) in the intradural vertebral artery. The technical success rate was 100%. The mean severity of preprocedural stenosis was 82.7% Ϯ 8.9% and postprocedure stenosis was 13.5% Ϯ 10.2% ( Table 2) .
The overall 1-month stroke and/or death rate was 2% (95% confidence interval, 0.2%-7.0%). Ischemic stroke occurred in the distribution of the perforating arteries (pontine) in 2 patients (On-line Table 2 ), both of whom had undergone the procedure for high-grade basilar artery stenosis. Both of them had midpontine infarctions on the postprocedure MR imaging. One patient developed hemiparesis and ataxia within 24 hours after the procedure. The other patient developed hemiplegia and facial paral- ysis (central) 72 hours after the procedure. The patients were treated with anticoagulation and intravenous hypervolemic hemodilution. Both patients had good recovery (mRS of 0 and 1 at 30-day follow-up, respectively). None of the remaining 98 patients had any new neurologic deficits or died within the 30-day visit. No hemorrhagic stroke, myocardial infarction, or severe adverse events were observed in this study.
DISCUSSION
We observed a high technical success rate and low rate of 1-month stroke and/or death in patients with high-grade intracranial stenosis treated with intracranial stent placement within this prospective multicenter study. The study was designed after the completion of the SAMMPRIS trial and incorporated modifications in protocol from observations derived from trial results and subsequent expert recommendations. 8 Several factors may have contributed to the more favorable short-term results observed within the current study. Restriction of patient recruitment to high-volume centers and modifications in patient selection were probably important factors.
In the SAMMPRIS trial, 220 procedures were performed in 50 sites in the United States during 29 months with an average of Ͻ2 procedures at each site per year. 8 Such recruitment patterns suggest that either familiarity with the protocol or even operator experience differed from that in our study, which treated 30 patients per year at each site on an average. To participate as an interventionalist in the SAMMPRIS trial, the operator was required to demonstrate previous experience with 20 intracranial angioplasty/stent procedures, of which at least 3 procedures were performed with the Wingspan or Neuroform stent system (Stryker Neurovascular). 8 In the current study, an annual volume of Ͼ30 intracranial stent procedures sustained during the past 3 years was required. Our results are comparable with the recent data (1-month stroke and/or death rate of 4.4%-6.2%) derived from some high-volume centers (Ͼ100 cases per year). [17] [18] [19] A retrospective analysis of 96 patients treated with intracranial angioplasty and stent placement at 3 university-affiliated institutions in the United States reported that the overall 1-month stroke and/or death rate was 7.2% in the 69 SAMMPRIS-eligible group and 7.4% in the 27 SAMMPRIS-ineligible group. 20 The 30-day stroke and/or death rate was 3.3% and 10.2% in the SAMMPRIS-eligible, angioplasty-treated subgroup and the stent-treated subgroup, respectively. Patient selection, particularly exclusion of patients with recent ischemic events and those with perforating artery ischemic stroke (in specific contrast to SAMMPRIS) may have contributed to the favorable short-term results in our trial. Our trial recruited patients who had experienced an index ischemic event at least 3 weeks before recruitment, which is longer than the recommended 7-day interval (range, 7-19 days) in the SAMMPRIS trial. The longer time interval may have allowed plaque stabilization and spontaneous lysis of overlying thrombus and probably also reduced the risk of hemorrhagic transformation for patients with recent ischemic stroke (Ͻ3 weeks). 17, [21] [22] [23] An analysis of the National Institutes of Health Multicenter Wingspan Intracranial Stent Registry Study found that stent placement performed within 10 days of a qualifying ischemic event was associated with a higher rate of 30-day stroke and/or death compared with procedures performed after 10 days (8% versus 17%, P ϭ .06). 21, 24 In the SAMMPRIS trial, the rates of ischemic stroke, symptomatic hemorrhagic stroke, or any death within 1 month were 15.7% and 13.8% in the patients enrolled within 7 days or after 7 days of their qualifying event, respectively. 15 Exclusion of patients with recent ischemic stroke may also exclude those with the highest risk of an ischemic event recurrence; therefore, the benefit of stent placement in the reduction of stroke recurrence may also be diminished. We included patients with distal hypoperfusion and/or cortical involvement. The exclusion of patients with perforating artery ischemic stroke may have reduced the occurrence of this type of stroke postprocedurally. 25 However, in a post hoc analysis of the SAMMPRIS trial, the rate of postprocedural ischemic events was not higher among those recruited due to perforating artery ischemic stroke (0%) compared with those with TIAs (8.9%) or nonperforating artery ischemic strokes (14.3%). 15 Certain procedure-related factors such as clopidogrel load (Ϸ10%) and poststent angioplasty (Ϸ10%) performed in the SAMMPRIS trial were avoided in the current study and may have made some contribution to the differences in adverse event rates. Two additional aspects that could improve the results of the intracranial angioplasty and stent placement are improvement in device design and point-of-care testing for assessing the magnitude of platelet inhibition with antiplatelet medication. Although the self-expandable Wingspan stent with the over-the-wire technique was widely adapted because of the relative ease of delivery over balloon-expandable stents with the rapid-exchange technique; however, the effectiveness of the self-expanding stent in restoring lumen diameter and preventing restenosis has been questioned. Although the radial force exerted by the Wingspan is superior to that of other self-expandable stents such as the Enterprise (Codman & Shurtleff, Raynham, Massachusetts) and Neuroform stents, it is not comparable with that of balloon-expanding stents. A new generation of balloon-expanding stents with a rapid-exchange platform may result in superior technical results. We did not perform point-of-care testing to guide antiplatelet treatment in our cohort of patients. Point-of-care testing was introduced because considerable differences can be observed within individuals in regard to platelet inhibition with the same doses of aspirin and clopidogrel. 26 Such assessment may allow the use of higher doses of clopidogrel and intravenous glycoprotein IIb/IIIa inhibitors among those with inadequate response (resistance) to standard doses of antiplatelet medication. The low rate of adverse events following intracranial angioplasty and stent placement in our trial raises the question of the superiority of such a procedure over intense medical treatment for high-grade symptomatic intracranial stenosis. Intensive medical therapy in the SAMMPRIS trial consisting of aspirin, 325 mg/day, for entire follow-up; clopidogrel, 75 mg per day for 90 days after enrollment; and aggressive risk-factor management (targeting blood pressure Ͻ130/80 mm Hg and low-density lipoprotein concentration of Ͻ70 mg/dL) had reduced the 30-day stroke and/or death rate to 5.8%, which was substantially lower than the estimated rate of 10.7% based on historical controls. 8 Chaudhry et al 27 reported that a Յ3.8% 1-month rate of stroke and/or death was required to achieve a 35% relative risk reduction of the primary end point (composite of 1-month stroke and/or death and ipsilateral stroke beyond 1 month) among the intracranial stent-treated group compared with the medically treated group at 1-year follow-up, as specified by the superiority threshold within the SAMMPRIS hypothesis. One of the limitations in our study was the restrictions posed by sample size. We provided the 95% confidence interval values to provide quantitative assessment of the precision of the estimate. Although the current 1-month stroke and/or death rates seen following intracranial stent placement are encouraging, our study does not provide any information regarding the long-term results in regard to both clinical events and restenosis. Based on the results of the current study, the China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis trial has been initiated and is an ongoing, prospective, multicenter randomized trial, which is being conducted in 8 sites intending to recruit 380 subjects (stent placement, 190; medical treatment alone, 190). 28 The study aims to demonstrate a 10.7% absolute reduction in ipsilateral stroke and/or death during 12 months (assuming an event rate of 18% for medically treated patients 3 and 7.3% for stenttreated patients 19 ). The sample size provides 80% power with a 2-sided test at the 5% level of significance and provides a 20% rate of lost follow-up.
